SMMT

Summit Therapeutics Inc

Add to Watchlist

Advanced Chart

26.290

-0.4(-1.499%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

26.730

Open

26.270

VWAP

26.32

Vol

2.33M

Mkt Cap

19.53B

Low

25.320

Amount

61.42M

EV/EBITDA(TTM)

Total Shares

701.98M

19.23B

EV/OCF(TTM)

P/S(TTM)

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

-0.111

+23.59%

-0.140

+75.64%

0.071

-188.82%

Estimates Revision

The market is revising No Change the revenue expectations for Summit Therapeutics Inc. (SMMT) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 9.50%.

EPS Estimates for FY2025

Revise Downward

-1.72%

In Past 3 Month

Stock Price

Go Up

+9.50%

In Past 3 Month

12 Analyst Rating

Wall Street analysts forecast SMMT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SMMT is 35.38 USD with a low forecast of 30.00 USD and a high forecast of 44.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

0 Hold

1 Sell

Strong Buy

Current: 26.290

Low

30.00

Averages

35.38

High

44.00

Current: 26.290

Low

30.00

Averages

35.38

High

44.00

Piper Sandler

Hold

initiated

$21

2025-08-18

New

Reason

Piper Sandler

Price Target

$21

2025-08-18

New

initiated

Hold

Reason

Piper Sandler initiated coverage of Summit Therapeutics with a Neutral rating and $21 price target.

Clear Street

Buy

maintain

$30 -> $33

2025-08-12

Reason

Clear Street

Price Target

$30 -> $33

2025-08-12

maintain

Buy

Reason

Clear Street raised the firm's price target on Summit Therapeutics to $33 from $30 and keeps a Buy rating on the shares following the Q2 report. The firm views the earnings print as "largely uneventful" with no fundamental changes on Summit's research and development programs. Clear Street continues to view ivonescimab as the "front-runner in a novel class of medicines with several multi-billion-dollar oncology opportunities."

Citi

Buy

maintain

$35

2025-08-12

Reason

Citi

Price Target

$35

2025-08-12

maintain

Buy

Reason

Citi views the going concern language in Summit Therapeutics' quarterly filing as a "non-issue." The company can use equity, shareholders or partnerships to raise capital and auditors only count current cash on hand, the analyst tells investors in a research note. Citi keeps a Buy rating on Summit shares with a $35 price target post the Q2 report. The stock in afternoon trading is down 12%, or $3.48, to $24.78.

UBS

NULL -> Buy

initiated

$30

2025-06-30

Reason

UBS

Price Target

$30

2025-06-30

initiated

NULL -> Buy

Reason

UBS initiated coverage of Summit Therapeutics with a Buy rating and $30 price target. The firm believes Summit's lead program, ivonescimab, could become the new standard of care in front-line non-small cell lung cancer with a greater than $7B peak sales opportunity, or $11B unadjusted, while the stock is pricing in about $5B, the analyst tells investors.

Leerink

Underperform

initiated

$12

2025-06-11

Reason

Leerink

Price Target

$12

2025-06-11

initiated

Underperform

Reason

Leerink initiated coverage of Summit Therapeutics with an Underperform rating and $12 price target. Ivonescimab, Summit Therapeutics' VEGF-A/PD-1 bispecific, is a strong product and Summit leadership deserves credit for licensing ex-China rights to the bispecific from Akeso long before the clinical outcomes were clearly compelling, the firm says. However, Leerink does not believe Ivonescimab is the next Keytruda. For the firm, consensus estimates assume an unrealistic share of the current anti-PD(L)1 total addressable market, given the intense and heterogenous competitive landscape, and compared to the PD-(L)1 era, higher threshold for clinical success, regulatory approval, and uptake.

Clear Street

Bill Maughan

initiated

$33

2025-05-22

Reason

Clear Street

Bill Maughan

Price Target

$33

2025-05-22

initiated

Reason

Clear Street analyst Bill Maughan last night initiated coverage of Summit Therapeutics with a Buy rating and $33 price target. Summit is a biotechnology company developing a single asset, ivonescimab, which is "the most exciting pipeline molecule in oncology today," the analyst tells investors in a research note. The firm says ivonescimab has already shown in multiple Phase 3 clinical studies that it can outperform standard-of-care immunotherapy, including the "best-selling global medicine" Keytruda in non-small cell lung cancer.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Summit Therapeutics Inc (SMMT.O) is -91.67, compared to its 5-year average forward P/E of -17.17. For a more detailed relative valuation and DCF analysis to assess Summit Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-17.17

Current PE

-91.67

Overvalued PE

6.01

Undervalued PE

-40.34

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-12.64

Current EV/EBITDA

-38.71

Overvalued EV/EBITDA

8.77

Undervalued EV/EBITDA

-34.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

376.13

Current PS

173.09

Overvalued PS

996.20

Undervalued PS

-243.94